Major Developments: SSY GROUP (02005) has obtained production registration approval for Doxazosin Mesylate Sustained-Release Tablets (4mg) and other pharmaceutical products. SBP GROUP (01177) announced that its CDK2/4/6 inhibitor, "Kumoxili Capsules," has received approval for a new indication in first-line breast cancer treatment. BAIJIN LIFE SCI (01466) subsidiary entered into a strategic cooperation framework agreement with Fuyao Yuanqi to collaborate in the field of clinical cell therapy. SSY GROUP (02005) obtained a medical device registration certificate from the Hebei Medical Products Administration for its full-range C-reactive protein (hsCRP + conventional CRP) detection kit and serum amyloid A/C-reactive protein (SAA/CRP) detection kit. Orient Securities (03958) plans to acquire 100% of Shanghai Securities through the issuance of A-shares and cash payment. SBP GROUP (01177) completed the first patient enrollment in a Phase III registration clinical trial for its CCR8 monoclonal antibody, "Kefeixi Bai Monoclonal Antibody," as a second-line treatment for gastric cancer. Kodi-B (02487) received marketing authorization from the National Medical Products Administration for CU-30101 (topical lidocaine-tetracaine cream).

Operating Performance: Jinxin Fertility (01951) reported a 7.5% year-on-year increase in initial infertility consultations and a 5.2% rise in egg retrieval cycles for the first four months. Muyuan Foods (02714) recorded a 32.49% decline in commercial hog sales revenue for April, totaling approximately RMB 8.503 billion. GAC Group (02238) sold 120,960 vehicles in April, up 3.88% year-on-year. First Pacific (00142) announced that MPIC achieved a consolidated core net profit of PHP 6.9 billion in the first quarter, representing a 5% increase.